A innovative antibody, XmAb 5592, exhibits a remarkable mechanism of action targeting IL17A with exceptional potency. Unlike conventional antibodies, it functions as a twofold modulator, binding to simultaneously the molecule and its control domain, leading to inhibition of interleukin-17A secretion